CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
- FinancialsAltman Z-Score 9.94: safe zone
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.26%
Annual Rate
CNY 0.16Paid annual
Payout Ratio
11.4%Sustainable
Last Ex-Dividend
Jul 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.66BCNY841.15M · vs all stocks (USD)
Trailing P/E
45.49xvs Biotechnology peers
Revenue (TTM)
896.26MCNY133.11M · vs all stocks (USD)
Profit Margin
14.91%vs Biotechnology peers
Beta
0.3880xvs all stocks
52-Week Change
14.58%vs all stocks
Market Capitalization
5.66BCNY841.15M · vs all stocks (USD)
Enterprise Value
4.42BCNY655.73M · vs all stocks (USD)
Trailing P/E
45.49xvs Biotechnology peers
Forward P/E
35.18xvs Biotechnology peers
Price to Sales (TTM)
6.86xvs Biotechnology peers
Price to Book (MRQ)
3.06xvs Biotechnology peers
Enterprise to Revenue
4.93xvs Biotechnology peers
Enterprise to EBITDA
34.49xvs Biotechnology peers
Gross Margin
30.19%vs Biotechnology peers
Profit Margin
14.91%vs Biotechnology peers
Operating Margin
12.00%vs Biotechnology peers
Return on Assets (TTM)
3.34%vs Biotechnology peers
Return on Equity (TTM)
6.96%vs Biotechnology peers
Revenue (TTM)
896.26MCNY133.11M · vs all stocks (USD)
Revenue per Share (TTM)
9.40CNYUpdated Aug 20, 2026Quarterly Revenue Growth
26.20%vs Biotechnology peers
Gross Profit (TTM)
298.35MCNY44.31M · vs all stocks (USD)
EBITDA (TTM)
140.64MCNY20.89M · vs all stocks (USD)
Net Income (TTM)
133.65MCNY19.85M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-12.50%vs Biotechnology peers
Operating Cash Flow (TTM)
107.32MCNY15.94M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
54.67MCNY8.12M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1603CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.26%vs all stocks
Payout Ratio
11.43%vs Biotechnology peers
Minority Interest (Equity)
7.56MCNYFY2025 · Dec 31, 2025Revenue
851.01MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
555.36MCNYFY2025 · Dec 31, 2025Gross Profit
295.64MCNYFY2025 · Dec 31, 2025Operating Income
135.02MCNY20.05M · vs all stocks (USD)
Pre-tax Income
155.15MCNYFY2025 · Dec 31, 2025Income Tax Expense
16.85MCNYFY2025 · Dec 31, 2025Net Income
138.29MCNYFY2025 · Dec 31, 2025EBIT
158.01MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
188.17MCNYFY2025 · Dec 31, 2025Research & Development
61.97MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
64.04MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.98MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
11.10MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.86MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
138.29MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.39MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
101.29MCNYFY2025 · Dec 31, 2025Free Cash Flow
82.03MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.12BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
138.29MCNYFY2025 · Dec 31, 2025Other Non-cash Items
8.37MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-49.72MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
4.35MCNYFY2025 · Dec 31, 2025Capital Expenditures
-19.26MCNYFY2025 · Dec 31, 2025Net Acquisitions
-24.00MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.23BCNYFY2025 · Dec 31, 2025Sale of Investments
2.29BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
19.11MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-55.14MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-11.78MCNYFY2025 · Dec 31, 2025Other Financing Charges
-2.11MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-69.03MCNYFY2025 · Dec 31, 2025Shares Outstanding
96.58MSharesUpdated Aug 20, 2026Float Shares
38.19MSharesUpdated Aug 20, 2026% Held by Insiders
61.47%vs all stocks
% Held by Institutions
9.81%vs all stocks
Total Cash (MRQ)
1.72BCNY255.31M · vs all stocks (USD)
Total Cash per Share (MRQ)
17.91CNYUpdated Aug 20, 2026Total Debt (MRQ)
7.04MCNY1.05M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0035xvs Biotechnology peers
Current Ratio (MRQ)
6.01xvs Biotechnology peers
Book Value per Share (MRQ)
20.80CNYUpdated Aug 20, 2026Total Assets
2.40BCNY356.39M · vs all stocks (USD)
Total Current Assets
2.16BCNYFY2025 · Dec 31, 2025Total Liabilities
423.89MCNYFY2025 · Dec 31, 2025Total Non-current Assets
244.34MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
38.81MCNYFY2025 · Dec 31, 2025Total Current Liabilities
385.07MCNYFY2025 · Dec 31, 2025Cash
1.11BCNYFY2025 · Dec 31, 2025Cash Equivalents
14.02MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.13BCNYFY2025 · Dec 31, 2025Other Short-term Investments
620.12MCNYFY2025 · Dec 31, 2025Accounts Receivable
133.47MCNYFY2025 · Dec 31, 2025Inventory
59.02MCNYFY2025 · Dec 31, 2025Accounts Payable
46.17MCNYFY2025 · Dec 31, 2025Short-term Debt
36.80MCNYFY2025 · Dec 31, 2025Other Current Liabilities
20.12MCNYFY2025 · Dec 31, 2025Long-term Debt
7.73MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
779.00CNYFY2025 · Dec 31, 2025Common Stock (Book)
96.58MCNYFY2025 · Dec 31, 2025Retained Earnings
801.09MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.98BCNY293.44M · vs all stocks (USD)
Treasury Stock
22.95MCNYFY2025 · Dec 31, 202552-Week Low
43.79CNYUpdated Aug 20, 202652-Week High
91.78CNYUpdated Aug 20, 202652-Week Change
14.58%vs all stocks
Beta
0.3880xvs all stocks
50-Day MA
51.48CNYUpdated Aug 20, 2026200-Day MA
60.74CNYUpdated Aug 20, 2026Avg 10-Day Volume
5.51MSharesUpdated Aug 20, 2026Avg 30-Day Volume
4.33MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
1.40CNYUpdated Aug 20, 20265 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Working Capital Pattern
What customers owe has grown three years running, while it clears stock quickly and pays suppliers quickly.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Financial Health
Altman Z-Score 9.94: safe zoneNotable
Altman Z-Score: 9.94
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Pharming Group N.V.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Hongyu Wuzhou Medica Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Genfit S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chengdu Shengnuo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shouyao Holdings Beijing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gansu Longshenrongfa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
HK inno.N Corporation
Tier 1ProductionApproval-Gated PipelineRule
Beijing Chunlizhengda Medical Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Solid Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Harmony Biosciences Holdings, Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksRevenue Growing With Receivables GrowingWorking Capital PatternMulti-Year FCF With Growth And Margin
Global Ship Lease Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksRevenue Growing With Receivables GrowingWorking Capital PatternMulti-Year FCF With Growth And Margin
Powell Industries Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksRevenue Growing With Receivables GrowingWorking Capital PatternMulti-Year FCF With Growth And Margin